- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
J&J reports high foot-infection cure rate with experimental antibiotic
New Brunswick, N.J. - Johnson & Johnson says its experimental antibiotic ceftobiprole was found to cure 86 percent of patients with diabetic foot infections, Bloomberg.com reports.
New Brunswick, N.J. - Johnson & Johnson says its experimental antibiotic ceftobiprole was found to cure 86 percent of patients with diabetic foot infections, Bloomberg.com reports.
Johnson & Johnson, based here, reported the data at a recent medical meeting in San Diego, Calif. The company says the drug also cured methicillin-resistant Staphylococcus aureus (MRSA) infections.
Johnson & Johnson licenses the drug from Swiss co-developer Basilea Pharmaceutica AG.
Ceftobiprole’s 86 percent foot-infection cure rate compares with 81.8 percent reported for a combination therapy using vancomycin, an approved antibiotic, according to Johnson & Johnson.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
